## 1) The “beat” is less about a quarter and more about *proof of commercial pull-through* GRAIL’s Q4 performance showed Galleri demand translating into real dollars, with **Q4 2025 total revenue up 14% Y/Y to $43.6M** and **U.S. Galleri revenue up 31% Y/Y to $41.3M**—a clean indicator that adoption is broadening, not just “early adopter noise.” ["total revenue grew 14%"](0001699031-26-000009|1) ["U.S. Galleri revenue grew 31%"](0001699031-26-000009|1) Importantly, the company also anchored the year on *scale metrics*: **“Sold more than 185,000 Galleri tests in 2025”** and **U.S. Galleri revenue grew 26% Y/Y to $136.8M**, which implies the commercialization engine is now large enough that incremental distribution wins (health systems + digital channels) can compound. ["Sold More Than 185,000"](0001699031-26-000009|1) ["U.S. Galleri revenue grew 26%"](0001699031-26-000009|1) ## 2) Operating leverage is starting to show—while the market is still focused on losses Even with headline losses, the directionality matters: in Q4, **gross loss improved** and management highlighted **non-GAAP adjusted gross profit of $23.1M** and **non-GAAP adjusted EBITDA of $(71.8)M**. ["Gross loss was $11.1 million"](0001699031-26-000009|1) ["Non-GAAP adjusted gross profit was $23.1 million"](0001699031-26-000009|1) ["non-GAAP adjusted EBITDA was $(71.8) million"](0001699031-26-000009|1) For FY2025, the same “quiet” improvement is clearer: **non-GAAP adjusted gross profit rose to $73.6M (+27% Y/Y)** and **non-GAAP adjusted EBITDA improved 34% to $(320.6)M**—signals of fixed-cost absorption as volume grows. ["Non-GAAP adjusted gross profit was $73.6 million"](0001699031-26-000009|1) ["Adjusted gross profit was $73.6 million, an increase"](0001699031-26-000009|1) ["non-GAAP adjusted EBITDA was $(320.6) million"](0001699031-26-000009|1) ["an improvement of $163.0 million or 34%"](0001699031-26-000009|1) ## 3) The real optionality: FDA PMA + a newly created Medicare on-ramp Two disclosures matter for “alpha between the lines” because they compress the time between *clinical evidence → regulatory status → coverage logic*: - **Regulatory milestone:** GRAIL completed the **final module** of the **Galleri PMA submission in January**, with the PMA package anchored in PATHFINDER 2 and the prevalent round of NHS-Galleri plus a bridging analysis. ["Completed submission of the final module"](0001699031-26-000009|1) ["bridging analysis"](0001699031-26-000009|1) - **Policy catalyst:** the **Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act** became **federal law**, explicitly **creating a Medicare coverage pathway** for MCED tests. ["became federal law"](0001699031-26-000009|1) ["Medicare coverage pathway"](0001699031-26-000009|1) The combined read-through: if PMA approval is achieved, reimbursement friction could shift from “will Medicare ever cover this?” to “how quickly can stakeholders operationalize the pathway?”, which is a different (and often faster) adoption curve. ## 4) NHS-Galleri: headline miss, but the *commercially relevant* endpoint moved the right way Yes—the trial **did not meet** its **primary endpoint** of a statistically significant **combined Stage III–IV reduction**. ["did not meet the primary endpoint"](0001699031-26-000009|1) ["primary endpoint of statistically significant Stage III-IV reduction was not observed"](0001699031-26-000009|2) But the signal GRAIL will lean into (and that payors often care about) is **late-stage avoidance at the extreme**: the trial showed a **“substantial” reduction in Stage IV diagnoses**, including **“greater than 20%” reductions in the second and third rounds** for a pre-specified group of 12 deadly cancers. ["substantial and clinically meaningful reduction"](0001699031-26-000009|2) ["greater than 20% reduction"](0001699031-26-000009|2) Hidden-in-plain-sight detail: GRAIL is already positioning the dataset to improve with time—disclosing **plans to extend follow-up by 6–12 months** and citing that time-to-diagnostic-resolution improved as physicians gained experience. ["extend the trial’s follow up period by 6-12 months"](0001699031-26-000009|2) ["time to diagnostic resolution appears to improve"](0001699031-26-000009|2) ## 5) Funding runway buys them time to “force-multiply” distribution—while a known margin headwind is deferred Management’s disclosures point to a plan to keep investing through the regulatory/coverage window: cash and short-term investments were **$904.4M at year-end 2025**, and the company has repeatedly messaged **runway into 2030** alongside **2026 guidance of 22–32% revenue growth and <$300M cash burn**. ["totaled $904.4 million"](0001699031-26-000009|1) ["2026 guidance: 22–32% growth"](0001628280-26-001786|1) ["2026 guidance: <$300M"](0001628280-26-001786|1) ["Runway2 into 2030"](0001628280-26-001786|1) On the “future gross margin” concern: the Illumina royalty is real, but the most recent filings clarify timing—**a high single-digit oncology royalty is suspended until the earlier of December 24, 2026 or a change of control**, after which it becomes payable (i.e., not a 2027 start by default). ["suspended until the earlier of December 24, 2026"](0001699031-25-000193|0) ["high-single digit royalty"](0001699031-25-000193|0) **Bottom line:** the quarter matters, but the investable “edge” is that GRAIL is simultaneously (1) scaling commercial demand, (2) bending cost structure in the right direction, and (3) aligning regulatory + legislative rails that could convert Galleri from an LDT-driven product into an FDA-and-Medicare-enabled category—despite an NHS primary endpoint miss that’s likely to be debated loudly. ["Sold More Than 185,000"](0001699031-26-000009|1) ["Completed submission of the final module"](0001699031-26-000009|1) ["became federal law"](0001699031-26-000009|1) ["primary endpoint… was not observed"](0001699031-26-000009|2)

## 1) The “beat” is less about a quarter and more about *proof of commercial pull-through* GRAIL’s Q4 performance showed Galleri demand translating into real dollars, with **Q4 2025 total revenue up 14% Y/Y to $43.6M** and **U.S. Galleri revenue up 31% Y/Y to $41.3M**—a clean indicator that adoption is broadening, not just “early adopter noise.” ["total revenue grew 14%"](0001699031-26-000009|1) ["U.S. Galleri revenue grew 31%"](0001699031-26-000009|1) Importantly, the company also anchored the year on *scale metrics*: **“Sold more than 185,000 Galleri tests in 2025”** and **U.S. Galleri revenue grew 26% Y/Y to $136.8M**, which implies the commercialization engine is now large enough that incremental distribution wins (health systems + digital channels) can compound. ["Sold More Than 185,000"](0001699031-26-000009|1) ["U.S. Galleri revenue grew 26%"](0001699031-26-000009|1) ## 2) Operating leverage is starting to show—while the market is still focused on losses Even with headline losses, the directionality matters: in Q4, **gross loss improved** and management highlighted **non-GAAP adjusted gross profit of $23.1M** and **non-GAAP adjusted EBITDA of $(71.8)M**. ["Gross loss was $11.1 million"](0001699031-26-000009|1) ["Non-GAAP adjusted gross profit was $23.1 million"](0001699031-26-000009|1) ["non-GAAP adjusted EBITDA was $(71.8) million"](0001699031-26-000009|1) For FY2025, the same “quiet” improvement is clearer: **non-GAAP adjusted gross profit rose to $73.6M (+27% Y/Y)** and **non-GAAP adjusted EBITDA improved 34% to $(320.6)M**—signals of fixed-cost absorption as volume grows. ["Non-GAAP adjusted gross profit was $73.6 million"](0001699031-26-000009|1) ["Adjusted gross profit was $73.6 million, an increase"](0001699031-26-000009|1) ["non-GAAP adjusted EBITDA was $(320.6) million"](0001699031-26-000009|1) ["an improvement of $163.0 million or 34%"](0001699031-26-000009|1) ## 3) The real optionality: FDA PMA + a newly created Medicare on-ramp Two disclosures matter for “alpha between the lines” because they compress the time between *clinical evidence → regulatory status → coverage logic*: - **Regulatory milestone:** GRAIL completed the **final module** of the **Galleri PMA submission in January**, with the PMA package anchored in PATHFINDER 2 and the prevalent round of NHS-Galleri plus a bridging analysis. ["Completed submission of the final module"](0001699031-26-000009|1) ["bridging analysis"](0001699031-26-000009|1) - **Policy catalyst:** the **Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act** became **federal law**, explicitly **creating a Medicare coverage pathway** for MCED tests. ["became federal law"](0001699031-26-000009|1) ["Medicare coverage pathway"](0001699031-26-000009|1) The combined read-through: if PMA approval is achieved, reimbursement friction could shift from “will Medicare ever cover this?” to “how quickly can stakeholders operationalize the pathway?”, which is a different (and often faster) adoption curve. ## 4) NHS-Galleri: headline miss, but the *commercially relevant* endpoint moved the right way Yes—the trial **did not meet** its **primary endpoint** of a statistically significant **combined Stage III–IV reduction**. ["did not meet the primary endpoint"](0001699031-26-000009|1) ["primary endpoint of statistically significant Stage III-IV reduction was not observed"](0001699031-26-000009|2) But the signal GRAIL will lean into (and that payors often care about) is **late-stage avoidance at the extreme**: the trial showed a **“substantial” reduction in Stage IV diagnoses**, including **“greater than 20%” reductions in the second and third rounds** for a pre-specified group of 12 deadly cancers. ["substantial and clinically meaningful reduction"](0001699031-26-000009|2) ["greater than 20% reduction"](0001699031-26-000009|2) Hidden-in-plain-sight detail: GRAIL is already positioning the dataset to improve with time—disclosing **plans to extend follow-up by 6–12 months** and citing that time-to-diagnostic-resolution improved as physicians gained experience. ["extend the trial’s follow up period by 6-12 months"](0001699031-26-000009|2) ["time to diagnostic resolution appears to improve"](0001699031-26-000009|2) ## 5) Funding runway buys them time to “force-multiply” distribution—while a known margin headwind is deferred Management’s disclosures point to a plan to keep investing through the regulatory/coverage window: cash and short-term investments were **$904.4M at year-end 2025**, and the company has repeatedly messaged **runway into 2030** alongside **2026 guidance of 22–32% revenue growth and <$300M cash burn**. ["totaled $904.4 million"](0001699031-26-000009|1) ["2026 guidance: 22–32% growth"](0001628280-26-001786|1) ["2026 guidance: <$300M"](0001628280-26-001786|1) ["Runway2 into 2030"](0001628280-26-001786|1) On the “future gross margin” concern: the Illumina royalty is real, but the most recent filings clarify timing—**a high single-digit oncology royalty is suspended until the earlier of December 24, 2026 or a change of control**, after which it becomes payable (i.e., not a 2027 start by default). ["suspended until the earlier of December 24, 2026"](0001699031-25-000193|0) ["high-single digit royalty"](0001699031-25-000193|0) **Bottom line:** the quarter matters, but the investable “edge” is that GRAIL is simultaneously (1) scaling commercial demand, (2) bending cost structure in the right direction, and (3) aligning regulatory + legislative rails that could convert Galleri from an LDT-driven product into an FDA-and-Medicare-enabled category—despite an NHS primary endpoint miss that’s likely to be debated loudly. ["Sold More Than 185,000"](0001699031-26-000009|1) ["Completed submission of the final module"](0001699031-26-000009|1) ["became federal law"](0001699031-26-000009|1) ["primary endpoint… was not observed"](0001699031-26-000009|2)